Faze Medicines is a pharmaceutical company developing interventions against biomolecular condensates, a newly-discovered driver of disease pathology. Biomolecular condensates, highly dynamic clusters of protein and RNA or DNA, have recently been shown to play an important role in diseases such as amyotrophic lateral sclerosis (ALS), Huntington’s Disease, and cancer.  Faze was founded by leaders at the forefront of this exciting new field and aims to revolutionize the treatment of diseases driven by aberrant biomolecular condensates by developing small molecule drugs that address condensate dysregulation. Faze is initially targeting biomolecular condensates implicated in neurodegenerative disorders such as ALS and Myotonic Dystrophy 1 (MD1) given the well-established role of condensates in these indications.